Leerink Partnrs Has Negative Estimate for RCUS Q3 Earnings

Key Points

• Leerink Partners has significantly downgraded its Q3 2025 earnings estimate for Arcus Biosciences to ($1.34) per share, down from a previous estimate of ($1.09).
• In its recent quarterly report, Arcus Biosciences posted earnings of ($1.11) per share and had a revenue increase of 310.3% year-over-year, totaling $160 million.
• Several financial firms have lowered their price targets for Arcus Biosciences, with Barclays setting a new low target of $14.00, while the overall consensus rating remains a "Moderate Buy".

Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) - Research analysts at Leerink Partnrs cut their Q3 2025 earnings per share (EPS) estimates for Arcus Biosciences in a research note issued on Thursday, August 7th. Leerink Partnrs analyst D. Graybosch now expects that the company will post earnings of ($1.34) per share for the quarter, down from their previous forecast of ($1.09). The consensus estimate for Arcus Biosciences' current full-year earnings is ($3.15) per share. Leerink Partnrs also issued estimates for Arcus Biosciences' Q4 2025 earnings at ($1.26) EPS, FY2025 earnings at ($3.74) EPS, Q1 2026 earnings at ($0.87) EPS, Q2 2026 earnings at ($0.93) EPS, Q3 2026 earnings at ($1.00) EPS, Q4 2026 earnings at ($1.01) EPS and FY2026 earnings at ($3.82) EPS.

Arcus Biosciences (NYSE:RCUS - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported ($1.11) EPS for the quarter, topping the consensus estimate of ($1.14) by $0.03. The company had revenue of $160.00 million for the quarter, compared to analyst estimates of $32.86 million. Arcus Biosciences had a negative return on equity of 55.96% and a negative net margin of 109.56%. The firm's revenue was up 310.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.02) earnings per share.

Several other brokerages also recently weighed in on RCUS. The Goldman Sachs Group lowered their target price on Arcus Biosciences from $15.00 to $13.00 and set a "neutral" rating on the stock in a research note on Thursday, May 8th. Wells Fargo & Company decreased their price target on Arcus Biosciences from $26.00 to $25.00 and set an "overweight" rating on the stock in a research note on Thursday, August 7th. Wall Street Zen upgraded Arcus Biosciences from a "strong sell" rating to a "hold" rating in a research note on Saturday, August 9th. Barclays decreased their price target on Arcus Biosciences from $29.00 to $14.00 and set an "overweight" rating on the stock in a research note on Wednesday, April 23rd. Finally, Wedbush restated an "outperform" rating and issued a $33.00 price target on shares of Arcus Biosciences in a research note on Wednesday, May 7th. Three equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $21.14.

Arcus Biosciences Stock Performance

RCUS traded down $0.18 during trading on Monday, hitting $9.88. 251,334 shares of the stock were exchanged, compared to its average volume of 1,031,702. The firm has a market capitalization of $1.05 billion, a P/E ratio of -3.11 and a beta of 0.89. Arcus Biosciences has a 1-year low of $6.50 and a 1-year high of $18.98. The stock has a fifty day moving average price of $9.15 and a two-hundred day moving average price of $9.39. The company has a quick ratio of 4.50, a current ratio of 4.50 and a debt-to-equity ratio of 0.18.

Institutional Trading of Arcus Biosciences

A number of institutional investors have recently bought and sold shares of RCUS. Gilead Sciences Inc. purchased a new stake in Arcus Biosciences during the fourth quarter worth $447,610,000. Woodline Partners LP raised its holdings in shares of Arcus Biosciences by 45.5% in the first quarter. Woodline Partners LP now owns 5,127,304 shares of the company's stock worth $40,249,000 after acquiring an additional 1,603,367 shares during the last quarter. Boxer Capital Management LLC acquired a new position in shares of Arcus Biosciences in the fourth quarter worth $23,857,000. Vanguard Group Inc. raised its holdings in shares of Arcus Biosciences by 24.1% in the first quarter. Vanguard Group Inc. now owns 6,687,800 shares of the company's stock worth $52,499,000 after acquiring an additional 1,298,584 shares during the last quarter. Finally, RA Capital Management L.P. acquired a new position in shares of Arcus Biosciences in the first quarter worth $8,920,000. 92.89% of the stock is currently owned by hedge funds and other institutional investors.

About Arcus Biosciences

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.